0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead's Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data were published in The New England Journal of Medicine, with new regulatory submissions underway to the FDA and EMA. The update centers on Trodelvy's role in Gilead's oncology pipeline and the potential for expanded use in breast cancer treatment. Gilead Sciences, listed as NasdaqGS:GILD, is drawing attention as it advances its oncology portfolio alongside its established antiviral franchise. The company's recent Trodelvy update arrives with the stock at $139.72, supported by returns of 8.2% over the past week, 11.9% over the past month, and 14.9% year to date. Over longer periods, returns of 50.3% over 1 year, 84.8% over 3 years, and 162.4% over 5 years reflect how investors have reacted to Gilead's evolving pipeline and business profile. For investors following oncology developments, the latest Trodelvy readout po [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead's Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data were published in The New England Journal of Medicine, with new regulatory submissions underway to the FDA and EMA. The update centers on Trodelvy's role in Gilead's oncology pipeline and the potential for expanded use in breast cancer treatment. Gilead Sciences, listed as NasdaqGS:GILD, is drawing attention as it advances its oncology portfolio alongside its established antiviral franchise. The company's recent Trodelvy update arrives with the stock at $139.72, supported by returns of 8.2% over the past week, 11.9% over the past month, and 14.9% year to date. Over longer periods, returns of 50.3% over 1 year, 84.8% over 3 years, and 162.4% over 5 years reflect how investors have reacted to Gilead's evolving pipeline and business profile. For investors following oncology developments, the latest Trodelvy readout po [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS